Achieve Life Sciences Long-Term Debt | ACHV

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Achieve Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
11.2 M	9.84 M	6 K	69 K	14.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
14.9 M	6 K	7.2 M

Quarterly Long-Term Debt Achieve Life Sciences

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5 K	9.32 M	66 K	8.67 M	8.66 M	8.66 M	9.84 M	9.82 M	8.8 M	-	6 K	16.2 M	15.7 M	54 K	69 K	15.8 M	15.5 M	15.2 M	14.9 M	23 K	41 K	59 K	77 K	77 K	77 K	77 K	159 K	159 K	20 K	24 K	12 K	12 K	-	12 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
16.2 M	5 K	4.94 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	602 K	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	38 K	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	79.3 K	-	-6.08 %	$ 184 M	China
Synthetic Biologics SYN	1.67 M	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	26.4 M	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	84.7 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	2.13 B	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	23.1 M	-	-	$ 866 M	China
BeyondSpring BYSI	307 K	$ 0.84	34.27 %	$ 34.5 M	USA
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	10.2 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	2.44 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	33.6 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	338 K	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	124 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	95.8 M	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	7.45 M	-	-	-	Russia
Galera Therapeutics GRTX	1.12 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	93.1 K	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	1.31 M	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	8.8 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	7 K	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	6.66 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	6.52 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	118 K	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	151 K	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	80.6 M	-	-	$ 344 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
AnaptysBio ANAB	12 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	24.2 M	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	2 K	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	46.5 M	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	52.3 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	1.21 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	1.93 M	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	43 K	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	962 M	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	669 K	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	140 M	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	436 K	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada